LRRC19

Chr 9

leucine rich repeat containing 19

LRRC19 encodes a pathogen-recognition receptor that mediates NF-kappaB signaling pathway activation and induces pro-inflammatory cytokine expression, particularly important for preventing uropathogenic bacterial infections in the kidney and regulating host-microbiota interactions in the gut. The gene shows very low constraint against loss-of-function variants (pLI near 0, LOEUF 1.777), and no established Mendelian disease associations have been reported to date. Clinical significance of LRRC19 variants in pediatric patients remains unclear given the lack of documented disease phenotypes.

OMIMResearchSummary from RefSeq, UniProt
MultiplemechanismLOEUF 1.78
Clinical SummaryLRRC19
Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
75 unique Pathogenic / Likely Pathogenic· 63 VUS of 154 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
1.78LOEUF
pLI 0.000
Z-score -0.72
OE 1.21 (0.821.78)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint
-0.44Z-score
OE missense 1.09 (0.971.23)
193 obs / 176.7 exp
Tolerant

Tolerant to missense variation

Observed / Expected Ratios
LoF OE1.21 (0.821.78)
00.351.4
Missense OE1.09 (0.971.23)
00.61.4
Synonymous OE1.23
01.21.6
LoF obs/exp: 16 / 13.2Missense obs/exp: 193 / 176.7Syn Z: -1.45
DN
0.6939th %ile
GOF
0.6736th %ile
LOF
0.2872th %ile

This gene has evidence for multiple mechanisms of pathogenicity (dominant-negative and gain-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to dominant-negative as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

DNprediction above median
GOFprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

154 submitted variants in ClinVar

Classification Summary

Pathogenic69
Likely Pathogenic6
VUS63
Likely Benign11
Benign1
69
Pathogenic
6
Likely Pathogenic
63
VUS
11
Likely Benign
1
Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
69
0
69
Likely Pathogenic
0
0
6
0
6
VUS
0
49
14
0
63
Likely Benign
0
8
1
2
11
Benign
1
0
0
0
1
Total157902150

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

LRRC19 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

3D Protein StructureAlphaFold

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →